A Clinical Study for Assessment of the Efficacy and Safety of Mirtazapine (Smilon) in Depression Patients With Pain

Inclusion Criteria: * Male or female * Age 20-65 years * Diagnosis of at least one chronic pain syndrome and the diagnosis of concomitant depression according to DSM-IV criteria * Have a mean weekly pain score of at least 30 mm on the 100-mm visual analog scale (VAS) of the Short-Form McGill Pain Questionnaire (SF-MPQ) before study entry Exclusion Criteria: * Women of child bearing potential who are pregnant, breastfeeding or not using effective contraceptives * Known hypersensitivity to Mirtazapine or any of its components * Subjects who have a clinically significant or unstable medical or psychiatric condition * Subjects who have received nerve blocks or acupuncture for pain relief